AU2009238667A1 - Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof - Google Patents

Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof Download PDF

Info

Publication number
AU2009238667A1
AU2009238667A1 AU2009238667A AU2009238667A AU2009238667A1 AU 2009238667 A1 AU2009238667 A1 AU 2009238667A1 AU 2009238667 A AU2009238667 A AU 2009238667A AU 2009238667 A AU2009238667 A AU 2009238667A AU 2009238667 A1 AU2009238667 A1 AU 2009238667A1
Authority
AU
Australia
Prior art keywords
veev
ires
alphavirus
cells
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009238667A
Other languages
English (en)
Inventor
Ilya V. Frolov
Elena Frolova
Scott C. Weaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2009238667A1 publication Critical patent/AU2009238667A1/en
Priority to AU2014265084A priority Critical patent/AU2014265084B2/en
Priority to AU2016228199A priority patent/AU2016228199B2/en
Priority to AU2018229512A priority patent/AU2018229512B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2009238667A 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof Abandoned AU2009238667A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2014265084A AU2014265084B2 (en) 2008-01-24 2014-11-21 Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
AU2016228199A AU2016228199B2 (en) 2008-01-24 2016-09-14 Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
AU2018229512A AU2018229512B2 (en) 2008-01-24 2018-09-13 Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24
US61/062,229 2008-01-24
PCT/US2009/000458 WO2009131604A2 (en) 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014265084A Division AU2014265084B2 (en) 2008-01-24 2014-11-21 Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Publications (1)

Publication Number Publication Date
AU2009238667A1 true AU2009238667A1 (en) 2009-10-29

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009238667A Abandoned AU2009238667A1 (en) 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Country Status (15)

Country Link
US (3) US8426188B2 (https=)
EP (2) EP2250269B1 (https=)
JP (1) JP5758632B2 (https=)
KR (2) KR101668849B1 (https=)
CN (1) CN102083986B (https=)
AU (1) AU2009238667A1 (https=)
CA (2) CA2910235C (https=)
CO (1) CO6290702A2 (https=)
IL (2) IL207167A (https=)
MX (3) MX367792B (https=)
MY (1) MY178870A (https=)
NZ (2) NZ603790A (https=)
SG (2) SG187513A1 (https=)
WO (1) WO2009131604A2 (https=)
ZA (1) ZA201005943B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2947149T3 (en) * 2007-06-21 2018-06-06 Alphavax Inc ALPHAVIRUS REPLICATION PARTICLES FOR USE IN VACCINATION
SG187513A1 (en) 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
EP2900685B1 (en) 2012-09-27 2017-10-25 Research Development Foundation Attenuated chikungunya virus
JP6426695B2 (ja) 2013-03-14 2018-11-21 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. 弱毒生アルファウイルス製剤のための組成物および方法
US20190106682A1 (en) * 2016-03-31 2019-04-11 Takeda Vaccines, Inc. Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
CN109476708B (zh) * 2016-05-27 2023-12-22 格里菲斯大学 针对致关节炎甲病毒的疫苗
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
CA3111440A1 (en) * 2018-08-03 2020-02-06 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
CA2533614C (en) 2004-07-30 2011-05-03 Research In Motion Limited Method and system for coordinating device setting between a communications client and its host device
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
SG187513A1 (en) * 2008-01-24 2013-02-28 Univ Texas Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Also Published As

Publication number Publication date
EP2250269A2 (en) 2010-11-17
EP2250269A4 (en) 2012-01-04
MX378503B (es) 2025-03-11
JP5758632B2 (ja) 2015-08-05
JP2011523347A (ja) 2011-08-11
CA2910235C (en) 2021-07-06
US20110052634A1 (en) 2011-03-03
CN102083986B (zh) 2014-06-18
KR101668849B1 (ko) 2016-10-24
MY178870A (en) 2020-10-21
SG10201606111XA (en) 2016-09-29
KR20100106599A (ko) 2010-10-01
US20170240919A1 (en) 2017-08-24
US8426188B2 (en) 2013-04-23
EP3085787A1 (en) 2016-10-26
EP2250269B1 (en) 2016-03-16
CA2713165C (en) 2015-12-29
IL232032A0 (en) 2014-05-28
NZ603790A (en) 2014-08-29
US10533186B2 (en) 2020-01-14
US20140010841A1 (en) 2014-01-09
KR20160124255A (ko) 2016-10-26
ZA201005943B (en) 2011-04-28
KR101913790B1 (ko) 2018-12-28
CN102083986A (zh) 2011-06-01
MX367792B (es) 2019-09-05
EP3085787B1 (en) 2020-10-28
CA2910235A1 (en) 2009-10-29
US9580690B2 (en) 2017-02-28
IL207167A0 (en) 2010-12-30
CO6290702A2 (es) 2011-06-20
NZ587502A (en) 2012-12-21
CA2713165A1 (en) 2009-10-29
IL207167A (en) 2014-04-30
WO2009131604A2 (en) 2009-10-29
SG187513A1 (en) 2013-02-28
MX2019010530A (es) 2019-10-15
MX2010007989A (es) 2010-12-21
WO2009131604A3 (en) 2009-12-23

Similar Documents

Publication Publication Date Title
US10533186B2 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
Paessler et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic
White et al. Role of alpha/beta interferon in Venezuelan equine encephalitis virus pathogenesis: effect of an attenuating mutation in the 5′ untranslated region
Aréchiga-Ceballos et al. Alphaviral equine encephalomyelitis (Eastern, Western and Venezuelan)
Erasmus et al. Novel insect-specific eilat virus-based chimeric vaccine candidates provide durable, mono-and multivalent, single-dose protection against lethal alphavirus challenge
Volkova et al. IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells
KR20090008193A (ko) 가감염성 플라비바이러스 및 이들의 용도
US20190106682A1 (en) Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
US8343506B2 (en) Chimeric chikungunya virus and uses thereof
US9402890B2 (en) Methods and compositions for pseudoinfectious alphaviruses
AU2018229512B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
AU2014265084B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
HK1230647A1 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
Attenuated Recombinant Sindbis/Venezuelan Equine
WO2007002793A2 (en) Chimeric sindbis-eastern equine encephalitis virus and uses thereof
Vander Veen et al. A manuscript submitted to Animal Health Research Reviews

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted